Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Academish Medisch Centrum currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and is located within 1 distinct art unit. The prosecution focus is highly concentrated due to the limited number of active applications currently under review by the patent office. This narrow scope suggests a specific and targeted intellectual property strategy for the current period.
DAVIS, BRIAN J is identified as the busiest examiner for the portfolio, managing 1 pending office action. With only 1 distinct examiner involved, the current prosecution strategy is focused on a single point of contact at the patent office. This concentration in 1 distinct art unit reflects a specific technical focus within the Biotechnology & Pharmaceuticals sector. Practitioners should prioritize understanding the specific examination preferences of this individual to efficiently navigate the pending matter. Because of the current workload, the overall administrative burden on the portfolio remains low.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, BRIAN J | 1 | 84.8% | -4.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554382 | WNT AGONISTS FOR PREVENTION OF CANCER | DAVIS, BRIAN J | 70d |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18554382 | WNT AGONISTS FOR PREVENTION OF CANCER | DAVIS, BRIAN J | 1614 | §103 | Non-Final OA | 70d | Pending | Oct 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial